酒精性肝病患者血清IL-33高水平的临床意义*

doi:10.3969/j.issn.1672-5069.2015.02.012

实用肝脏病杂志 ›› 2015, Vol. 18 ›› Issue (2): 156-159.doi: 10.3969/j.issn.1672-5069.2015.02.012

酒精性肝病患者血清IL-33高水平的临床意义^*

郝书理, 张纪元, 黄昂, 张龙玉, 孙颖, 李保森, 田辉, 邹正升

100039北京市北京大学医学部教学医院/解放军第302医院非感染性肝病诊疗中心（郝书理,黄昂,张龙玉,孙颖,李保森,田辉,邹正升）; 肝病生物治疗研究中心（张纪元）

收稿日期:2014-11-14 出版日期:2015-03-10 发布日期:2016-02-19
通讯作者: 邹正升,E-mail:zszou302@163.com
作者简介:郝书理,女,25岁,硕士研究生。E-mail:haoshuli302@163.com
基金资助:
国家自然科学基金资助项目（No.81370530）

Clinical significance of increased serum IL-33 levels in patients with alcoholic liver diseases

Hao Shuli, Zhang Jiyuan, Huang Ang, et al.

Non-infectious Liver Disease Diagnosis and Treatment Center,302nd Hospital, Beijing 100039,China

Received:2014-11-14 Online:2015-03-10 Published:2016-02-19

摘要/Abstract

摘要： 目的探讨血清IL-33异常升高在酒精性肝病（ALD）发病中的作用及其临床意义。方法应用ELISA法检测40例酒精性肝炎、17例重症酒精性肝炎、75例酒精性肝硬化和48例健康人血清IL-33及其可溶性受体ST2（sST2）水平,分析血清IL-33水平与临床生化指标的相关性。结果酒精性肝炎、重症酒精性肝炎和酒精性肝硬化患者血清IL-33水平分别为（85.20±9.44） pg/ml、（68.70±8.14） pg/ml和（64.45±3.78） pg/ml,均显著高于健康人[（42.17±2.41）pg/ml,P<0.001],且酒精性肝炎患者血清IL-33水平较酒精性肝硬化患者明显升高（P<0.05）,而在重症酒精性肝炎患者和酒精性肝硬化患者不同Child-Pugh分级组间差异无显著性（P>0.05）;酒精性肝炎、重症酒精性肝炎和酒精性肝硬化患者血清sST2水平分别为（96.75±11.30） pg/ml、（51.92±11.78） pg/ml和（75.82±6.81）pg/ml,均显著高于健康人[（43.97±3.01） pg/ml,P<0.001],且酒精性肝炎患者血清sST2水平较重症酒精性肝炎或酒精性肝硬化明显升高（P<0.001或P<0.05）,而酒精性肝硬化Child-Pugh A组患者较B级或C级明显升高（P 均<0.001）;ALD患者外周血清IL-33水平与sST2无明显相关性,IL-33水平与淋巴细胞计数（R=0.273,P<0.01）、白蛋白（R=0.237,P<0.01）、ALT（R=0.462,P<0.001）、AST（R=0.387,P<0.001）和胆碱脂酶（R=0.225,P<0.01）水平呈显著正相关,而血清IL-33水平与中性粒细胞、总胆红素、碱性磷酸酶、总胆固醇和凝血酶原活动度水平无显著相关性。结论酒精性肝病患者血清升高的IL-33可能促进了患者免疫反应而诱导疾病的进展。

关键词: 酒精性肝病, 白细胞介素-33, 可溶性受体ST2, 临床指标

Abstract: Objective To explore the changes of serum IL-33 levels in patients with alcoholic liver diseases. Methods Serum levels of IL-33 and its soluble receptor sST2 in patients with alcoholic hepatitis（n=40）, severe alcoholic hepatitis（n=17）,alcoholic liver cirrhosis（n=75）,and healthy individuals （n=20） were measured by ELISA. IL-33 and sST2 levels in different groups were compared and the correlation between serum IL-33 levels and the regular biochemical indexes was analyzed. Results Patients with alcoholic hepatitis,severe alcoholic hepatitis and cirrhosis had elevated serum IL-33 levels than that in the controls[（85.20±9.44） pg/ml,（68.70±8.14） pg/ml,（64.45±3.78） pg/ml vs. （42.17±2.41） pg/ml,P<0.001 for all],while IL-33 in patients with alcoholic hepatitis were significantly higher than that in cirrhotic patients（P<0.05）;however,there was no statistical difference between patients with severe hepatitis and cirrhosis with different Child-Pugh class;Serum sST2 in alcoholic hepatitis,severe alcoholic hepatitis and cirrhosis group significantly elevated compared to that in the controls [（96.75±11.30） pg/ml,（51.92±11.78） pg/ml,（75.82±6.81） pg/ml vs. （43.97±3.01） pg/ml,P<0.001 for all],while serum sST2 levels in patients with alcoholic hepatitis was higher than that in patients with severe hepatitis or cirrhosis（P<0.001 and P<0.05,respectively）;in addition,serum sST2 in patients with alcoholic cirrhosis with Child-Pugh A class was significantly higher than those in cirrhotic patients with Child-Pugh B class or C class（P<0.001 for both）;there was no correlation between serum IL-33 and sST2（R=0.100,P=0.180）;Serum IL-33 levels in patients with alcoholic liver disease showed positive correlation with lymphocyte counts（R=0.273,P<0.01）,ALB（R=0.237,P<0.01）,ALT（R=0.462,P<0.001）,AST（R=0.387,P<0.001）and CHE（R=0.225,P<0.01）,while no significant correlation with neutrophils,TBIL,ALP,GGT,TC and PTA. Conclusion Elevated serum IL-33 levels might contribute to the development of alcoholic liver disease by aggravating immunological reaction.

Key words: Alcoholic liver diseases, Interleukin-33, SolubleST2, Clinical index

郝书理, 张纪元, 黄昂, 张龙玉, 孙颖, 李保森, 田辉, 邹正升. 酒精性肝病患者血清IL-33高水平的临床意义^*[J]. 实用肝脏病杂志, 2015, 18(2): 156-159.

Hao Shuli, Zhang Jiyuan, Huang Ang, et al.. Clinical significance of increased serum IL-33 levels in patients with alcoholic liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(2): 156-159.

参考文献

[1] Schmitz J, Owyang A,Oldham E,et al. IL-33,an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity,2005,23（5）:479-490.
[2] Marvie P,Lisbonne M,L'helgoualc'h A,et al. Interleukin-33 overexpression is associated with liver fibrosis in mice and humans. J Cell Mol Med,2010,14（6B）:1726-1739.
[3] 王洪岩,李鑫,徐有青. 酒精性肝病发病机制研究进展. 实用肝脏病杂志,2014,17（1）:5-8.
[4] O'Shea RS,Dasarathy S,McCullough AJ. Alcoholic liver disease. Hepatology,2010,51（1）:307-328.
[5] Gao B,Bataller R. Alcoholic liver disease：pathogenesis and new therapeutic targets. Gastroenterology,2011,141（5）:1572-1585.
[6] Mello T,Ceni E,Surrenti C,et al. Alcohol induced hepatic fibrosis：role of acetaldehyde. Mol Aspects Med,2008,29（1-2）:17-21.
[7] Cruz A,Muntane J. Alcoholic liver disease,oxidative stress,and antioxidants. Rev Esp Enferm Dig,2011,103（8）:393-395.
[8] Harrison-Findik DD,Schafer D,Klein E,et al. Alcohol metabolism-mediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression. J Biol Chem,2006,281（32）:22974-22982.
[9] 李鑫,王晨,聂娇,等. 酒精性肝炎小鼠肝肠组织变化与内毒素血症的关系探讨. 实用肝脏病杂志,2013,16（3）:254-256.
[10] Voican CS,Perlemuter G,Naveau S. Mechanisms of the inflammatory reaction implicated in alcoholic hepatitis：2011 update. Clin Res Hepatol Gastroenterol,2011,35（6-7）:465-474.
[11] Endo M,Masaki T,Seike M,et al. TNF-alpha induces hepatic steatosis in mice by enhancing gene expression of sterol regulatory element binding protein-1c（SREBP-1c）. Exp Biol Med（Maywood）,2007,232（5）:614-621.
[12] Barksby HE,Lea SR,Preshaw PM,et al. The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clin Exp Immunol,2007,149（2）:217-225.
[13] Werman A,Werman-Venkert R,White R,et al. The precursor from of IL-alpha is an intracrine proinflammatory activator of transcription. Proc Natl Acad Sci USA,2004,101（8）:2434-2439.
[14] 谢莉,朱平. IL-33在免疫相关疾病中的研究进展. 免疫学杂志,2013,29（6）:535-539.
[15] Hayakawa H,Hayakawa M,Kume A,et al. Soluble ST2blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem,2007,282（36）:26369-26380.

酒精性肝病患者血清IL-33高水平的临床意义^*

Clinical significance of increased serum IL-33 levels in patients with alcoholic liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	延喜胜, 李伟, 王剑. 酒精性肝病患者血清细胞因子水平和肠道菌群分布变化研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 518-521.
[2]	王海舫, 杨大伟, 贾蓓, 张岁, 柳立平, 马文波, 解从君, 刘明书. 营养支持联合美他多辛治疗酒精性肝病患者肝功能和外周血细胞参数的变化[J]. 实用肝脏病杂志, 2019, 22(3): 381-384.
[3]	张岱,王炳元. 酒精性肝炎的诊断与挑战^*[J]. 实用肝脏病杂志, 2019, 22(2): 153-155.
[4]	孙韬华,刘振胜,辛永宁. 酒精性肝病治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(2): 156-159.
[5]	郭宝娜, 展玉涛. 酒精性肝病79例临床特征分析[J]. 实用肝脏病杂志, 2018, 21(6): 877-880.
[6]	刘露露, 王炳元. 肠道微生态与酒精性肝病[J]. 实用肝脏病杂志, 2017, 20(6): 660-662.
[7]	陈源文, 范建高. 2016年《实用肝脏病杂志》精彩回顾[J]. 实用肝脏病杂志, 2017, 20(1): 1-3.
[8]	翁丽媚, 王炳元. 酒精性肝病的临床评估[J]. 实用肝脏病杂志, 2017, 20(1): 7-9.
[9]	叶茂聪, 李阳, 肖丽, 杨秀珍, 耿爱文, 沈美龙, 咸建春, 徐洪涛. 155例酒精性肝病患者临床特征分析^*[J]. 实用肝脏病杂志, 2017, 20(1): 60-64.
[10]	姜浩, 戈宏焱. 熊去氧胆酸联合脂溶性维生素注射液治疗酒精性肝病伴肝内胆汁淤积患者疗效观察[J]. 实用肝脏病杂志, 2017, 20(1): 105-106.
[11]	张龙玉，孙颖，黄昂，郝书理，李保森，张纪元，邹正升. 酒精性肝病患者肝组织NLRP3炎症复合体基因水平检测及其意义[J]. 实用肝脏病杂志, 2016, 19(6): 678-682.
[12]	王转国, 付强, 乐永红, 庄小芳, 王宏峰. 酒精性肝病患者肝组织cyp2e-3基因水平变化[J]. 实用肝脏病杂志, 2016, 19(5): 561-564.
[13]	温博, 徐贝贝, 王炳元. 美他多辛对酒精性肝病大鼠肝损伤的保护作用与抑制肝组织内炎性细胞因子水平有关[J]. 实用肝脏病杂志, 2016, 19(5): 565-569.
[14]	周慧友, 郑万玲, 江成, 许善虹, 文婷, 高凌峰. 海南鲜椰子水对酒精性肝损伤大鼠的保护作用研究^*[J]. 实用肝脏病杂志, 2016, 19(5): 570-573.
[15]	范建高. 2014年《实用肝脏病杂志》精彩回顾[J]. 实用肝脏病杂志, 2015, 18(1): 4-5.